Recombinant Trypanosoma cruzi Cruzipain Protein ，His & Myc

Cruzipain is a cysteine protease derived from the protozoan parasite *Trypanosoma cruzi*, the causative agent of Chagas disease, which affects millions of people, primarily in Latin America. This enzyme plays a crucial role in the parasite's lifecycle and pathogenesis, facilitating processes such as host cell invasion and immune evasion. Given its importance, cruzipain has become a significant target for drug development, with the potential to lead to novel therapeutic strategies against Chagas disease. Traditional treatments are often inadequate, prompting researchers to explore cruzipain inhibitors that could selectively disrupt the enzyme's function, thereby impairing the parasite's ability to survive in the host. The recombinant production of cruzipain allows for comprehensive structural and functional studies, which can elucidate its mechanisms and identify effective inhibitors. Understanding the enzyme's structure-function relationships is essential for designing targeted drugs that can effectively combat the disease and improve patient outcomes. Consequently, research on cruzipain continues to be critical not only for developing new pharmacological therapies but also for advancing the overall understanding of *T. cruzi* biology and pathogenicity.